Benzinga | Sep 30, 2021 11:45AM EDT

Scholar Rock Presents Exploratory Responder Analysis On Efficacy Data From Apitegromab TOPAZ Phase 2 Trial At Child Neurology Society Annual Meeting

Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a late breaker poster presentation as part of the 50th Child Neurology Society (CNS) Annual Meeting taking place September 29-October 2, 2021 Virtual and Live in Boston, MA.

Details for the Poster at the CNS meeting are as follows:

* Title: Efficacy of Apitegromab in Patients with Later-Onset Spinal Muscular Atrophy (SMA Types 2 and 3): Responder Analysis from the Phase 2 TOPAZ Study (#310) This late breaking poster presentation includes exploratory responder analyses on Hammersmith scale scores, including time to achieve various thresholds of improvement in Hammersmith Functional Motor Scale Expanded (HFMSE) scores. Live poster presentation (#310) will be available on September 30, 2021, from 11:45am- 6:30pm ET during the exhibits and posters open session. In addition, posters will be available during the exhibits and poster review sessions with authors on September 30 from 12:00-1:00pm ET, 5:30-6:30pm and October 1, 2021, from 7:00-8:00am ET. This poster will be published in the 2021 Annals of Neurology supplement or the CNS Annual Meeting Program

Scholar Rock will have a physical booth (#915) at the Hynes Convention Center, Exhibit Halls C & D, as well as a virtual booth at the meeting.

Live Exhibit Hall Times:

* Wednesday, September 29 from 6:00-7:30pm ET

* Thursday, September 30 from 11:30am-6:30pm ET Friday, October 1 from 7:00-10:30am ET